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Pediatric pharmacotherapy is often challenging due to the paucity of available clinical data on the
safety and efficacy of drugs that are commonly used in children This quandary is even more preva-
lent in children with rare diseases. Although extrapolations for dosing and administration are often
made from available adult data with similar disease states, this translation becomes even more prob-
lematic in rare pediatric diseases. Understanding of rare disease pathophysiology is typically poor,
and few, if any, effective therapies have been studied and identified. One condition that illustrates
these issues is plastic bronchitis, a rare, most often pediatric disease that is characterized by the pro-
duction of obstructive bronchial airway casts. This illness primarily occurs in children with congeni-
tal heart disease, often after palliative surgery. Plastic bronchitis is a highly clinically relevant and
therapeutically challenging problem with a high mortality rate, and, a generally accepted effective
pharmacotherapy regimen has yet to be identified. Furthermore, the disease is ill defined, which
makes timely identification and treatment of children with plastic bronchitis difficult. The pharmaco-
therapies currently used to manage this disease are largely anecdotal and vary between the use of
macrolide antibiotics, mucolytics, bronchodilators, and inhaled fibrinolytics in a myriad of combina-
tions. The purpose of this review is 2-fold: first, to highlight the dilemma of treating plastic bronchi-
tis, and second, to bring attention to the continuing need for studies of drug therapies used in
children so safe and effective drug regimens can be established, particularly for rare diseases.
KEY WORDS congenital heart disease, Fontan procedure, adverse effects, pulmonary disease, fibrinoly-
sis, antiinflammatory agents.
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In 1963, Dr. Harry Shirkey described children
as “therapeutic orphans” with regard to the
pharmacologic treatments tested and available
for this population.1 Numerous factors have
been identified that contribute to this problem,
ranging from a lack of financial incentives for
pharmaceutical companies to conduct such stud-
ies to concerns over the ethics of carrying out
nontherapeutic trials in this age demographic.2
Multiple legislative measures, notably the
Orphan Drug Act in 1983, the Food and Drug
Administration (FDA) Modernization Act in
1997, and the Best Pharmaceutical for Children
Act in 2002, sought to address some of these
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shortcomings by providing incentives for phar-
maceutical companies to conduct studies in the
pediatric population.1–3 More extensive rules to
safeguard this orphan population were estab-
lished by the Pediatric Research Equity Act in
2003, which required pediatric clinical studies
for all new biologics and drugs entering the mar-
ket unless a waiver or deferral is granted by the
FDA.3 Although increases in industry-sponsored
pediatric studies have resulted from these acts,
nearly 80% of commercially available drugs are
not labeled for use in children, and only one
third of the drugs used in pediatric patients have
been sufficiently studied in the disease states for
which they are being used.1–3 Many of the dos-
age regimens used in children have been extrap-
olated from available adult pharmacokinetic and
pharmacodynamic data.4 Based on these statis-
tics alone, it is not surprising that the practice
of off-label use of drugs has become widespread
among health care professionals who care for
pediatric patients. Reluctance to begin a therapy
due to adverse events or the alternative of start-
ing treatments due to fears over withholding a
potentially beneficial therapy contribute addi-
tional dilemmas to the therapeutic decision mak-
ing of clinicians providing care to this
population.2
These issues are further complicated in pedi-
atric patients with rare diseases for which few
treatments have been studied and successfully
used. Approximately 8000 diseases have been
categorized as rare, and it is estimated that
6–10% of the global population is living with
one of these conditions.5 Only 200 of the
several thousand rare diseases have approved
therapies, and only about one fourth of avail-
able orphan drugs have been designated for
use in rare pediatric diseases.3, 6 Many of these
illnesses develop in childhood and can be
progressively debilitating, presenting significant
challenges for patients, families, and health
care providers.5 The limited knowledge of
disease pathologies further complicates the abil-
ity to identify and utilize safe and efficacious
therapies.5
Plastic bronchitis (PB) is a rare disease in
which these shortcomings in pediatric pharma-
cotherapy can be aptly illustrated. The patho-
physiology of this condition remains poorly
understood, treatment regimens are mostly anec-
dotal, and morbidity and mortality are signifi-
cant.7–10 The goal of this review is to highlight
the therapies that are used in this population in
the absence of clinical efficacy and safety data.
Select patient cases are included to illustrate key
concepts in the diagnosis and management of
PB. This review also seeks to bring attention to
the need for continued work in the field of pedi-
atric pharmacotherapy so that safe and effective
therapies can be identified for children.
Plastic Bronchitis
Plastic bronchitis is a predominantly pediatric
disease characterized by the formation of
obstructive bronchiolar casts in the lung air-
ways.7–10 Its etiology and overall prevalence
remain unknown, but it most often occurs in
children with congenital heart disease (CHD)
surgically palliated by the Fontan procedure.11–13
Plastic bronchitis has also been reported as a
secondary complication in a variety of pulmo-
nary conditions, including asthma, cystic fibro-
sis, and acute chest syndrome.9, 10, 14, 15 Casts
have been described as “rubbery” in consistency
and have been reported to be composed of
fibrin, mucin, or both, depending on the under-
lying disease state.10, 13, 16 However, in children
with CHD, casts are primarily composed of
fibrin (Figure 1).10, 17
Although PB can develop in association with a
variety of conditions, it is particularly problem-
atic in the pediatric CHD population. This sub-
group experiences both the highest frequency of
Figure 1. A representative spontaneously expectorated
plastic bronchitis cast (~5 cm in length) from a pediatric
patient with Fontan-associated plastic bronchitis. Pathology
showed that it was primarily composed of fibrin.
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life-threatening events and the highest mortality
rate of any disease associated with PB.9 The clin-
ical presentation of PB generally manifests in
episodes of dyspnea, tachycardia, hypoxemia,
fever, and cough due to airway obstruc-
tion.8, 13, 14, 18, 19 The chest radiograph may
show opacification of the affected lung field due
to partial or full atelectasis.13, 14, 18, 20 However,
this observation is not useful as a definitive diag-
nostic tool.20 Presently, the diagnosis of PB
hinges on visualization of bronchial casts that
are either expectorated or removed by bronchos-
copy.7, 9 There are currently no phenotypic bio-
markers that assist in the diagnosis or
differentiation of Fontan patients who have or
are prone to develop the disease.
Classification systems of airway cast composi-
tion have been proposed to bring insight into
the etiology of cast formation. These schemes
seek to provide a formative guide for treatments
used in this population based on the cast type
and underlying disease state. The most widely
used scheme delineates casts into one of two
main types: type I (inflammatory) and type II
(acellular).21 Inflammatory, or type I, airway
casts were defined by the presence of fibrin,
eosinophilic infiltrates, and small amounts of
mucin.12, 21 Acellular, or type II, casts were dis-
tinguished by the presence of mucin, little to no
fibrin, and a lack of cellular content other than
mononuclear cells in some cases.21 In the case
reports examined by the authors of this classifi-
cation scheme, type I casts were produced by
patients with histories of pulmonary conditions,
such as asthma or diffuse mucositis, and type II
casts were primarily reported in patients with
surgically corrected CHD.12, 21 A revised classifi-
cation system was proposed in 2002 based on
the underlying disease state of the patient, which
included the categories of allergic or asthmatic,
cardiac, and idiopathic origins.9 Another classifi-
cation scheme was introduced in 2005, which
proposed diagnosis first according to the
primary disease state of the patient, and then by
cast histology if the underlying disease state was
not readily defined.16 Although these classifica-
tion schemes have been widely applied for
differentiating cast types, they were primarily
developed by using published case reports that
retrospectively examined available pathology
data of cast composition. Use of existing pathol-
ogy reports for this purpose could result in
incomplete information due to variations in his-
topathologic assessment between institutions and
the degree of completeness of the reports.10
More recently, a prospective, longitudinal
approach was used to assess cast composition,
and it determined that airway casts produced by
children with CHD were primarily composed of
fibrin, with very little mucin.10 This finding was
recently confirmed by a global protein profiling
approach to more completely define airway cast
composition.17 This study also noted that these
casts had cellular infiltrates, further challenging
the longstanding belief that casts from this PB
population are primarily acellular. Knowledge of
bronchial cast composition in the CHD popula-
tion is essential for elucidating the mechanisms
of airway cast formation, which in turn is imper-
ative for the identification of drug target oppor-
tunities aimed at preventing and reducing
airway cast burden in children with PB. This
finding also shifts the approach of PB cast char-
acterization from one that is disease-associated
to one that is focused on prospective histopatho-
logic assessment.
Insight into the Clinical Dilemma
The pharmacotherapy for PB is largely anec-
dotal and varies widely according to the under-
lying disease state and the severity of
symptoms.10, 13, 14, 18, 20 Treatments started in
response to acute exacerbations of PB typically
involve the initiation of inhaled mucolytics and
inhaled and systemic corticosteroids, and, if nec-
essary, bronchoscopic lavage and extraction of
obstructing airway casts.14, 15, 18, 20 Other
pharmacotherapies that have been used in this
population include aerosolized fibrinolyt-
ics,13, 14, 18, 20 macrolides,13, 18 bronchodila-
tors,13 anticoagulants,14, 20 and hypertonic saline
(Tables 1 and 2).13 The degree of efficacy of
each of these interventions remains widely
unknown, as use of these agents has primarily
been highlighted in case reports. As such, we
present the clinical cases of two patients with
recurrent episodes of PB to illustrate treatment
approaches used at our institution for manage-
ment of acute and chronic PB. Case number 1
highlights the complex initial presentation of a
patient who ultimately was diagnosed with PB
and also exemplifies the sporadic and unpredict-
able nature of airway cast formation and expec-
toration. Case number 2, which occurred
10 years after the initial presentation of Case
number 1, demonstrates the continued chal-
lenges of diagnosing PB. In particular, this case
shows how the absence of phenotypic markers
exclusive of airway cast visualization impairs the
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Table 1. Representative Therapies for the Management of an Acute Plastic Bronchitis Exacerbationa
Drug Indication Drug Class
Route of
Administration Typical Doses
Albuterol Airway clearance Bronchodilator Inhaled 2.5 mg every 4–6 hr prn
Levalbuterol Inhaled 0.63–1.25 mg every
4–6 hrs prn
Prednisone Antiinflammatory Corticosteroid Oral 1–2 mg/kg/day divided
1–2 times/day
Methylprednisone Intravenous 1–2 mg/kg/day divided
1–2 times/day
N-Acetylcysteine Airway cast
reduction
Mucolytic Inhaled Infants: 10% solution:
1–2 ml 3–4 times/day 20%
solution: 2–4 ml 3–4
times/day Children: 10%
solution: 3–5 ml 3–4 times/day
20% solution: 6–10 ml
3–4 times/day Adolescents:
10% or 20% solution:
5–10 ml 3–4 times/day
Dornase alfa Inhaled 2.5 mg 1–2 times/day
Alteplase (tPA) Fibrinolytic Inhaled Optional dose of 10–12 mg then
5 mg every 4–6 hrs
UFH Anticoagulant Inhaled Various regimens:
5000 units every 4–8 hrs
Subcutaneous Variable dosing
Prn = as needed; UFH = unfractionated heparin; tPA = tissue plasminogen activator.
aIn addition to supplemental oxygen and chest physiotherapy, these drugs may be used in a variety of combinations to facilitate airway cast
expectoration and reduce airway cast burden.
Table 2. Representative Therapies for the Chronic Management of Plastic Bronchitisa
Drugs Indication Drug Class
Route of
Administration Typical Doses
Albuterol Airway Clearance Bronchodilator Inhaled 2.5 mg every 4–6 hr prn
Levalbuterol Inhaled 0.63–1.25 mg every 4–6 hr prn
Budesonide-
formoterol
Corticosteroid-
bronchodilator
Inhaled 2 puffs twice/day (strength dependent
on age of patient)
Fluticosone-
Salmeterol
Inhaled 1 puff twice/day (strength dependent
on age of patient)
Hypertonic
Saline
(3% and 7%)
Inhaled 4 ml twice/day
Budesonide Antiinflammatory Corticosteroid Inhaled 0.25–1 mg tice/day
Azithromycin Macrolide Oral 250–500 mg 3 times/wk
Montelukast Leukotriene
Pathway
Inhibitor
Oral 6 mo–5 yrs: 4 mg/day
6–14 yrs: 5 mg/day
≥15 yrs: 10 mg/day
N-Acetylcysteine Airway cast
reduction
Mucolytic Inhaled Infants: 10% solution: 1–2 ml 3–4 times/day
20% solution: 2–4 ml 3–4 times/day
Children: 10% solution: 3–5 ml 3–4 times/day
20%: 6–10 ml 3–4 times/day Adolescents:
10% or 20% solution: 5–10 ml 3–4 times/day
Dornase alfa Inhaled 2.5 mg 1–2 times/day
Alteplase (tPA) Fibrinolytic Inhaled Optional dose of 10–12 mg then
5 mg every 4–6 hr
UFH Anticoagulant Inhaled Various regimens:
5000 units every 8 hr
Subcutaneous Variable dosing
Prn = as needed; UFH = unfractionated heparin; tPA = tissue plasminogen activator.
aSome of these drugs may be used in a variety of combinations with the intent to reduce cast formation and facilitate cast expectoration.
PEDIATRIC PLASTIC BRONCHITIS Brooks et al 925
timely identification and treatment of children
with PB.
Case Number 1
A child with hypoplastic left heart syndrome
diagnosed before birth underwent a series of
cardiac palliative procedures consisting of the
Norwood, hemi-Fontan, and fenestrated Fontan
procedures by the age of 17 months. His medi-
cal history became significant for respiratory ill-
ness after completion of his final palliative
surgery. He was hospitalized for episodes of
pneumonia, parainfluenza bronchiolitis, and
respiratory distress secondary to the formation
of presumed chylous plugs in the airway. After
multiple hospitalizations, the goal of treatment
began to focus on the resolution of recurrent
chylous plug formation, and, as a result, the
patient underwent a right upper lobectomy with-
out complications. Despite this intervention, the
patient continued to produce airway casts that
required extraction by bronchoscopy.
The diagnosis of chylopoeisis respiratory fail-
ure was made 2 years after his Fontan surgery
after another hospitalization for recurrent cast
formation and the development of chylous effu-
sions. Bilateral chest tubes were placed for
drainage of chylous effusions, and bronchoscop-
ies were performed to aid in cast removal. A
lymphatic nuclear scan showed no signs of tho-
racic drainage, which dismissed the need for a
thoracic duct ligation. Airway clearance therapy
was started after improved oxygenation second-
ary to cast removal by bronchoscopy. This regi-
men consisted of intermittent positive-negative
pressure breathing, nebulized albuterol, and N-
acetylcysteine (Table 1). The patient did well
with these therapies, and his clinical status con-
tinued to improve. He was discharged from the
hospital on a regimen of subcutaneous unfrac-
tionated heparin (UFH) and albuterol as needed.
The patient attended routine follow-up visits
for the management of his chyloptysis, which
was later reclassified as PB. He experienced
intermittent flares of the condition concurrently
with the development of upper respiratory viral
infections. He was able to expectorate casts
without medical intervention, and did not have
any significant worsening of PB that warranted
hospitalization again until the age of 13.
As an adolescent, the patient has been hospi-
talized multiple times for PB exacerbations.
Most recently, he presented to the emergency
department with symptoms consistent with an
exacerbation of PB, including increased cough,
difficulties with breathing, and active cast pro-
duction. He was found to be afebrile, normoten-
sive, tachycardic, and hypoxic (83% on room
air), with the latter necessitating the use of oxy-
gen. The chest radiograph showed prominent
bilateral perihilar bronchovascular markings,
with no evidence of pleural effusion or pneu-
mothorax. Given the clinical presentation, there
was a suspicion of pneumonia, and antibiotic
and antiviral therapies were empirically started.
The patient’s maintenance PB regimen (Table 2)
was continued throughout the course of his
hospital stay, which included inhaled budeso-
nide, albuterol, azithromycin, prednisone, sub-
cutaneous heparin, inhaled tissue plasminogen
activator (tPA), and chest physiotherapy.
Increases in the dosing frequencies of inhaled
tPA, budesonide, and albuterol were imple-
mented for the management of the patient’s
acute PB flare (Table 1).
After the expectoration of several casts over
the next 24 hours, the patient’s oxygen satura-
tion increased to 89%, and his clinical status sig-
nificantly improved. As a result, he was
discharged home from the hospital the next day.
Case Number 2
A patient with a double-inlet left ventricle,
transposition of the great arteries, and mild aortic
arch hypoplasia diagnosed before birth under-
went a series of palliative surgeries by the age of
18 months, including a modified Norwood, a
hemi-Fontan, and a lateral tunnel fenestrated
Fontan. Four years after the Fontan procedure,
the patient developed a chronic cough with inter-
mittent chest congestion. After 2 weeks of pro-
gressively worsening symptoms, the patient was
hospitalized and diagnosed with pneumonia.
Treatment with azithromycin and cefotaxime was
started, and the patient was discharged 2 days
later on a 14-day course of amoxicillin-clavula-
nate and supplemental oxygen. Despite these
treatments, the patient continued to experience
intermittent cough and episodes of shallow
breathing, and unknown to the medical team,
was actively expectorating airway casts at home.
Subsequently, the patient produced a cast dur-
ing hospitalization and was diagnosed with PB.
Histologic examination of the cast showed fibrin
and inflammatory cells. Based on these findings,
a drug regimen focused on maintenance of air-
way clearance using levalbuterol and hypertonic
saline was prescribed by the pulmonologist
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(Table 2). The regimen also included monteluk-
ast and dornase alfa as needed for PB exacerba-
tions. Despite long-term use of these therapies,
the patient continued to experience recurrent
severe PB exacerbations that required hospital-
ization and more intensive pharmacologic treat-
ment with inhaled tPA and dornase alfa.
Plastic Bronchitis Pharmacotherapy
The management of PB can be divided into two
types of therapeutic regimens, chronic and acute,
depending on the clinical status of the patient. All
therapies are symptomatic, and no known cura-
tive therapy exists other than heart transplanta-
tion for the condition. Presently, chronic therapy
is aimed at maintaining airway clearance and tar-
geting potential underlying causes of cast forma-
tion. The primary focus of treatment of an acute
flare is to facilitate cast expectoration and reduce
airway cast mass. However, as illustrated by the
two patients’ cases and the evidence available in
published case reports, there are currently no
accepted standard therapeutic regimens for either
the prevention or treatment of PB. The regimens
presented for the management of acute (Table 1)
and chronic (Table 2) PB disease are representa-
tive of those that are employed at the University
of Michigan and at other centers that treat chil-
dren with PB (see Acknowledgments section).
Airway Clearance Regimens
Agents traditionally used for the maintenance
of airway clearance are used in the management
of PB to facilitate airway cast expectoration. Air-
way clearance regimens are similar to those used
in patients with cystic fibrosis and generally con-
sist of bronchodilator administration followed by
chest physiotherapy and nebulized hypertonic
saline. Chest physiotherapies have demonstrated
efficacy in prolonging mucociliary clearance in
cystic fibrosis22 and chronic bronchitis23 without
adversely affecting lung function. Although the
clinical phenotypes of cystic fibrosis and PB are
distinct, the commonality of airway obstruction
observed in each of the disease states warrants
the consideration of using airway clearance strat-
egies in patients with PB.
Bronchodilators
Both short- and long-acting bronchodilators
are used in the management of acute and
chronic PB. The potential benefits of bronchodi-
lators include increased mucociliary clear-
ance,24, 25 in vitro inhibition of eosinophil
chemotaxis,26 and the inhibition of mediator
release from mast cells in the airway.27 However,
unlike the reactive airways of cystic fibrosis and
asthma in which mucociliary clearance is
impaired,28 there is presently no evidence that
this mechanism is involved in PB. In fact, it has
been our observation that patients with PB have
normal pulmonary function in the absence of an
obstructing airway cast. Nevertheless, use of a
short-acting bronchodilator like albuterol or lev-
albuterol in advance of chest physiotherapy may
aid in the relaxation of bronchial smooth muscle
and ease the expectoration of airway casts
(Tables 1 and 2). Although the rationale for the
use of a long-acting bronchodilator may be the
same, there is no evidence that either short- or
long-acting agents are effective for this purpose.
Recent evidence showing that cast pathology
consists of inflammatory cells, including eosin-
ophils,17 may substantiate the use of a long-act-
ing bronchodilator for its antiinflammatory
activity in the treatment of PB. However, the
role of eosinophils in cast formation is not fully
understood, and there is no evidence to date
that the use of a long-acting bronchodilator has
any impact on airway cast formation or disease
progression.
Hypertonic Saline
Administration of aerosolized hypertonic saline
is intended to prolong hydration of airway sur-
faces and promote airway mucociliary clear-
ance.29 These effects have been attributed to an
increase in the osmotic gradient between airway
surface liquid and the epithelial cells of the lungs
after its administration, which in turn draws
water back into the lung airway and increases the
volume of the airway surface liquid. The induc-
tion of cough has also been noted as a result of
the changes in osmolality and the ionic composi-
tion of the airway.30 In addition to these effects,
hypertonic saline also demonstrates mucolytic
properties through its ability to dissociate extra-
cellular DNA from mucoproteins, in turn
permitting proteolysis by native enzymes.31 Anti-
inflammatory and immunomodulatory effects,
including inhibition of tumor necrosis factor-a–
induced nuclear factor–j B activation in pulmo-
nary epithelium,32 modification of the airway
cytokine profile in cystic fibrosis,33 and a reduc-
tion in superoxide anion production by neutroph-
ils in vitro34 have also been demonstrated.
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Collectively, these actions could be beneficial
in the treatment of PB. However, like bronchodi-
lators, the use of hypertonic saline in PB is cur-
rently aimed at facilitating cast expectoration.
This is highlighted in Case number 2, in which
nebulized hypertonic saline was started in con-
junction with other airway clearance therapies.
Whether hypertonic saline is efficacious in
improving overall clinical outcomes or cast for-
mation remains to be ascertained. Administra-
tion of hypertonic saline has been associated
with bronchoconstrictive responses, an effect
that could counter effective cast expectoration.35
Although the use of bronchodilators before this
therapy can alleviate this response, the implica-
tion of this effect in the management of PB
should be considered.
Antiinflammatory Therapies
Antiinflammatory therapies are routinely used
in the management of acute and chronic PB.
These therapies include inhaled and systemic
corticosteroids, macrolides, and leukotriene path-
way inhibitors. Although the etiology of this rare
disease is poorly understood, the fibrin and cellu-
lar composition of casts produced in PB implicate
the involvement of an inflammatory response in
cast formation. However, there is presently no
evidence that any of the following antiinflamma-
tory agents have disease-modifying activity.
Leukotriene Pathway Inhibitors
Use of cysteinyl-leukotriene receptor (Cys-
LTR) antagonists like montelukast for the
treatment of PB has arisen due to the antiinflam-
matory effects and efficacy of these drugs in the
treatment of patients with asthma.36, 37 These
agents inhibit the actions of leukotriene D4 by
directly binding to Cys-LTRs present on smooth
muscle cells and airway macrophages, subse-
quently attenuating leukotriene-mediated inflam-
matory effects.38, 39 This therapy has been
associated with decreases in airway eosinophilic
inflammation,40 reductions in the use of bron-
chodilator therapy, and improvements in asthma
symptoms and overall control.41 There is no
evidence to substantiate that PB is an eosinophil-
mediated airway disease, but eosinophilic infil-
trates have been noted in PB cast samples.17
Whether the addition of a Cys-LTR inhibitor to
the long-tem drug regimen of patients with PB
could aid in attenuating this response is not pres-
ently known. The patient in Case number 2
received and tolerated this therapy well for nearly
2 years. However, its use did not prevent subse-
quent PB exacerbations.
Macrolides
Long-term use of macrolide antibiotics,
namely azithromycin, has been shown to convey
a number of actions including increased mucosal
clearance, prevention of the formation of bacte-
rial biofilm, and reductions in bronchoconstric-
tion through the inhibition of cholinergic
responses in the smooth muscles of the air-
way.42–44 In addition, azithromycin has antiin-
flammatory activity that is evidenced by its
ability to decrease the synthesis of reactive oxy-
gen species, inhibit neutrophil activation and
mobilization, and stimulate neutrophil apoptosis.
However, these effects often take several weeks
of treatment before they are fully tangible and
are only exhibited by 14- and 15-member mac-
rolides.43 For these reasons, in addition to its
more favorable adverse effect profile when com-
pared with other agents, azithromycin is most
often the macrolide of choice.
Evidence for the efficacy of macrolide therapy
in PB is limited to a few case reports. One
study45 reported complete resolution of cast pro-
duction after the addition of low-dose azithro-
mycin therapy to a patient’s pharmacologic
regimen and also noted improvement in lung
volume and expiratory flow rates. Another case
report attributed the ability to reduce the fre-
quency of inhaled tPA administration to the
addition of long-term azithromycin therapy.14
The antibacterial activity of azithromycin likely
does not contribute to the potential benefit of its
use in PB as there is no evidence of an infectious
etiology or that bacterial byproducts contribute
to cast formation in the airways.
Corticosteroids
Both inhaled and systemic corticosteroids are
used in the short- and long-term management of
PB (Tables 1 and 2). Corticosteroids exert their
mechanism of action primarily by suppressing
the expression of numerous mediators and
inhibiting both the innate and adaptive immune
cell responses typically involved with allergic
and nonallergic inflammatory responses.46, 47
Immunomodulatory effects are also observed
with these agents.47 Typically, an inhaled corti-
costeroid is coupled with the administration of a
long-acting bronchodilator, as the use of both
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agents has been shown to be more efficacious
than monotherapy with either agent.27 The com-
bined use of budesonide and formoterol yields
elevated expression of glucocorticoid receptor
binding to glucocorticoid response elements and
subsequent induction of glucocorticoid recep-
tor–dependent mitogen-activated protein kinase
phosphatase 1 in macrophages.48 This combina-
tion therapy also permits the administration of a
lower dose of 200 lg of budesonide as it demon-
strates similar efficacy to that of a higher
800 lg-dose of budesonide alone,48, 49 poten-
tially minimizing the risk for adverse effects.
Beyond the observed pharmacologic benefits,
this therapy has also demonstrated improve-
ments in lung function and symptoms and
reductions in the frequency of exacerbations in
asthma patients receiving long-term treatment.49
However, the wealth of evidence for the use of
glucocorticoids in the treatment of asthma is not
met with a similar level of support for their use
in the treatment of PB. Of interest, the most
abundant cytokine in a recent sample of PB air-
way casts was macrophage migration inhibitory
factor (MIF).17 The MIF is an inflammatory
cytokine that is known to have the ability to
sustain inflammatory responses in the presence
of endogenous or exogenous glucocorticoids.50
As such, MIF may represent a potential drug tar-
get for PB.
In an effort to minimize toxicity, the use of
systemic corticosteroids is generally limited to
acute PB exacerbations, as was demonstrated in
Case number 1 (Table 1). Patients are generally
started on a short-term course of steroids with
either prednisone or methylprednisolone, the
doses of which are tailored to the individual
patient. Although adverse side effects are a con-
cern with this therapy, the systemic administra-
tion of corticosteroids has demonstrated efficacy
in minimizing hospitalizations and improving
pulmonary function in asthma patients with
acute exacerbations.51 Reductions in unsched-
uled medical visits, symptoms of dyspnea, and
the use of inhaled bronchodilators in asthma
patients after an 8-day tapered dosing regimen
have been reported as well.52 However, prospec-
tive assessments confirming the efficacy of
inhaled and systemic corticosteroids in this
patient population are lacking. One case report
described the complete resolution of cast pro-
duction after the initiation of oral prednisone
2 mg/kg/day in combination with inhaled beclo-
methasone dipropionate 600 lg/day.53 The dose
of systemic corticosteroid was eventually
tapered, whereas the inhaled corticosteroid ther-
apy was continued. Although the patient did not
have any additional PB flares during the 3-year
follow-up period, “tenacious secretions” were
found by bronchoscopy, suggesting that cortico-
steroid therapy alone may not lead to complete
resolution of PB. In addition, given the abun-
dance of MIF in PB airway casts, the utility of
corticosteroids for PB treatment warrants more
thorough investigation.17
Therapies Targeted at Airway Cast Reduction
Mucolytics
Mucolytic therapy in PB has widely stemmed
from the belief that airway casts are primarily
composed of mucin secondary to mucosal hy-
persecretion.16, 21 This can result in the obstruc-
tion of lung airways due to excessive mucosal
accumulation, the occurrence of which has been
observed in other respiratory diseases such as
cystic fibrosis, asthma, and chronic obstructive
pulmonary disease.28, 54 N-Acetylcysteine and
dornase alfa are mucolytic agents commonly
used in respiratory conditions to reduce mucosal
viscoelasticity, with dornase alfa being solely
indicated for cystic fibrosis. Both of these agents
have been used in the management of PB; how-
ever, the evidence for the efficacy of these thera-
pies for the treatment of PB is limited to case
reports.
Antoher study,9 completed an in vitro com-
parison of N-acetylcysteine, dornase alfa, uroki-
nase plasminogen activator (uPA), and tPA,
which showed that N-acetylcysteine possessed
the greatest ability to dissolve PB bronchial
casts. Other case reports have detailed success
with the direct instillation of dornase alfa onto
casts in the airway to facilitate removal by bron-
choscopy.55–57 Improvements in pulmonary
function after treatment with dornase alfa have
also been detailed.57 In contrast, another case
reported no change in cast size after the direct
instillation of dornase alfa onto a cast fragment
in the airway of a patient with PB.15
Although these case reports varied with regard
to the efficacy observed with mucolytic therapy,
this class of agents could be useful in the man-
agement of PB. Extracellular DNA can contrib-
ute to airway mucosal thickening, and this effect
is commonly observed in patients with cystic
fibrosis due to the degradation of neutrophils in
the airways.58 Airway casts from Fontan patients
contain inflammatory cells, extracellular DNA,
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and histones that could contribute to airway cast
formation.17 It is therefore plausible that dornase
alfa may be useful in reducing airway cast bur-
den because it hydrolyzes long, extracellular
DNA molecules into smaller fragments.59 As
described in Case number 2, dornase alfa was
used for an acute PB exacerbation to facilitate
cast expectoration. However, mucolytic therapy
alone is likely not a reliable strategy to effec-
tively manage PB, as casts are predominantly
composed of fibrin and cast formation most
likely arises from a number of complex pro-
cesses. The efficacy of dornase alfa alone has
been further brought into question in a more
recent case report in which topical application
of the agent failed to reduced airway cast
mass.15
The evidence supporting the hypothesis that
mucosal hypersecretion in patients with CHD
and PB is primarily based on retrospective
reviews of case reports, some of which do not
detail cast histology.9, 16, 21 In addition, some of
the CHD cases noted the presence of either
inflammatory cells or fibrin in addition to
mucin, which are features that are not typical of
mucosal hypersecretion. Histologic staining of
cast samples obtained from a longitudinal study
of PB airway cast pathology revealed that they
were primarily composed of fibrin and lympho-
cytes, and that composition did not change over
time.10 These findings were substantiated by
protein profiling using a sophisticated proteo-
mics approach.17 In both studies, mucin was
either evident in small amounts or not found.
Although these observations may seem extrane-
ous, clarification of cast histology is useful for
determining the utility of therapies aimed at
reducing cast mass as well as for providing
insight into the etiology of cast formation. As
such, patients who produce fibrin casts would
more likely benefit from the use a fibrinolytic
agent rather than mucolytics to reduce airway
cast burden.15
Unfractionated Heparin
Unfractionated heparin is a heavily sulfated
glycosaminoglycan that is primarily used for its
anticoagulant properties.60 This agent exerts its
main mechanism of action by inactivating
thrombin and factor Xa after its binding to
antithrombin, which prevents the conversion of
fibrinogen to fibrin. Heparin also possesses
antiinflammatory and immunoregulatory prop-
erties that have been demonstrated in a variety
of processes, including inhibition of inflamma-
tory mediators and lymphocyte activation, neu-
trophil chemotaxis, smooth muscle growth,
and complement activation.61, 62 As a result,
the use of UFH in an aerosolized dosage form
for the management of inflammatory lung dis-
eases has recently become an active area of
research.61, 62
Reductions in bronchoconstrictive response
have been observed in patients with exercise-
induced asthma after the administration of
inhaled UFH.63 In addition, attenuation of early
and reduced late allergic responses in patients
with asthma and house dust mite allergies has
also been noted with the use of this interven-
tion. In pediatric patients with smoke-inhalation
injuries, inhaled therapies of 5000 units of aero-
solized UFH and 3 ml of 20% N-acetylcysteine
alternated every 2 hours over a 7-day period
yielded significant improvements in a variety of
clinical outcomes.64 These were evidenced by
overall decreases in the rates of atelectasis, rein-
tubation attributed to respiratory failure, number
of ventilator days, and overall mortality. Of note,
smoke-inhalation injuries are characterized in
part by the formation of fibrinous, cellular casts
in the airway. Twice-daily administration of
inhaled UFH in patients with idiopathic pulmo-
nary fibrosis has also been found to be safe and
well tolerated.65 However, the efficacy of this
intervention in idiopathic pulmonary fibrosis has
yet to be determined. Like inhaled tPA, there is
the potential for adverse bleeding events, but
none have been observed in any studies con-
ducted to date.
Inhaled UFH use in PB has been documented
in two case reports, each of which reported suc-
cess with regimens of 5000 units every
8 hours66 and 5000 units every 4 hours during
acute exacerbations.67 One of the patients was
maintained on an inhaled regimen of 5000 units
every 8 hours for an additional 12 months until
she was tapered off of this therapy.67 Intrave-
nous or subcutaneous administration of UFH in
patients with PB has been documented in multi-
ple case reports with variable success.14, 20, 68
However, one report claimed nearly complete
resolution of fibrin cast formation using a regi-
men of UFH 5000 units/day administered subcu-
taneously in a patient with PB and CHD.68
Attempts at discontinuing the therapy were asso-
ciated with a recurrence of active cast produc-
tion. As outlined in Case number 1,
subcutaneous UFH has been used as a chronic
therapy for several years with no adverse events.
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However, the contribution this drug makes
toward curtailing airway cast formation is not
readily apparent.
The improvements in clinical status that have
been documented in studies and select case
reports to date encourage the continued evalua-
tion of inhaled UFH therapy for the management
of PB. However, attention must be paid to the
potential for serious adverse effects such as hem-
orrhage and thrombocytopenia that can occur
with this agent.68 Furthermore, the optimal dos-
age regimen and the mechanism by which UFH
may modulate airway cast formation require fur-
ther study.
Fibrinolytics
Inhaled fibrinolytics, and more specifically
recombinant tPA, constitute a more recent addi-
tion to the wide range of therapeutic interven-
tions used to manage acute exacerbations of PB.
As described in each of the patient cases, inhaled
tPA is typically administered every 4 hours for
the management of acute exacerbations of PB
(Table 1). The use of inhaled fibrinolytic therapy
for PB was first outlined in a report that used
aerosolized uPA every 4 hours at a dose of
40,000 units to acutely manage a patient with
PB.69 A reduction in cast size and tenacity was
noted. After this observation, expectorated casts
were treated in vitro with normal saline, uPA
300 units/ml or tPA 1000 units/mL. The results
of these experiments showed that casts were
unchanged after incubation in normal saline and
became “soft and friable” after incubation with
uPA. In contrast, the cast samples exposed to tPA
were completely degraded, a finding that has
been substantiated by another study.10 Based on
this observation, a later study,18 administered
inhaled tPA to a patient with PB and underlying
CHD after 5 days of failed treatment with bron-
chodilators, corticosteroids, antibiotics, and mu-
colytics. Marked clearance of the airways was
observed by bronchoscopy after the initiation of
this therapy, and significant improvements in
oxygen saturation levels were noted as well. Mul-
tiple, unrelated case reports detailing experiences
with inhaled tPA followed, each of which
reported varying degrees of success in resolving
airway cast burden.13–15, 18, 20 Importantly, no
adverse events in association with the use of this
intervention were noted in any of these cases.
Experience with inhaled tPA at the University of
Michigan has been consistent with these observa-
tions.
Although both uPA and tPA have been uti-
lized to reduce cast burden, the extent of cast
degradation observed with the administration of
tPA in both the clinical setting and experimental
models has encouraged the continued use of tPA
over other fibrinolytic agents.10, 15, 69 Tissue
plasminogen activator is a serine protease that
catalyzes fibrinolysis through direct conversion
of plasminogen to plasmin.70 Although all fibri-
nolytic agents exhibit this mechanism of action,
tPA demonstrates a higher affinity for fibrin
compared with other plasminogen activators.
This property in the context of fibrin airway cast
production, along with observations of a favor-
able response in clinical and experimental set-
tings, makes targeted delivery of this agent a
logical strategy to reduce airway cast burden.
However, to our knowledge, no clinical studies
have been conducted to assess the safety and
efficacy of inhaled tPA in patients with PB. Sub-
sequently, there is a scarcity of clinical data on
appropriate dosage regimens and potential toxic-
ities that may arise from repeated dosing by
inhalation for a drug that is typically given as a
single intravenous dose.71, 72
The doses of inhaled tPA utilized in PB case
reports have been extrapolated from adult sys-
temic dose recommendations for acute myocar-
dial infarction or acute ischemic stroke.18
Although this is an acceptable framework to use
when initially selecting doses of drugs for off-
label use, the regimen implemented in the clini-
cal setting of PB stands in great contrast to those
used for the FDA-approved indications and
route of administration.73, 74 Tissue plasminogen
activator is typically given intravenously in a
continuous, tapered dosing scheme over the
course of a few hours. However, repeated dosing
of inhaled tPA is required to target fibrin airway
casts, and this regimen can potentially span sev-
eral days in duration depending on the severity
of the exacerbation. Presently, the response to
inhaled tPA is monitored by pulse oximetry and
the frequency of cast expectoration. There are
no biomarkers of drug efficacy or safety to date.
One of the main concerns associated the use of
inhaled tPA is the potential for adverse bleeding
events, the likelihood of which could potentially
increase with prolonged and repeated administra-
tion of this drug. Preclinical studies examining
the safety of accelerated and prolonged dosing
regimens of a pulmonary formulation of tPA have
been conducted in healthy murine models in the
absence of airway fibrin.71, 72 Pulmonary-deliv-
ered tPA doses of 3 mg/kg every 2 hours for up to
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12 hours and 0.3 mg/kg/day divided twice daily
over a 28-day period were well tolerated. How-
ever, prolonged administration of doses exceed-
ing 1 mg/kg/day were associated with acute and
fatal pulmonary hemorrhage. Albeit no adverse
events have been reported to date with inhaled
tPA in humans, this could be due to the rarity of
PB and the overall infrequent use of inhaled tPA
for its treatment and not necessarily due to the
safety of currently used doses. This makes it all
the more important for continued work toward
establishing a safe and efficacious dosing regimen
of inhaled tPA for children with PB.
Conclusion
Despite numerous well-intended legislative
initiatives, there is still an unmet need for drug
testing in children. This urgency is even greater
in children with rare diseases. The clinically
challenging and perplexing problem of PB is an
example of this because it is associated with
high morbidity and mortality, and there is no
known effective pharmacotherapy. Certainly,
improving knowledge of disease pathogenesis is
likely to unveil drug target opportunities; how-
ever, in the meantime, the most promising
agents are those that are directed at airway cast
reduction. Given that PB casts are primarily
fibrin, agents aimed at preventing fibrin forma-
tion, such as inhaled UFH, and dissociating
fibrin, such as inhaled tPA, could be especially
useful.
Recently, more details about the inflammatory
nature of PB airway casts have emerged. Of note,
the most abundant cytokine in casts was MIF.
This finding raises the possibility that MIF could
be a potential drug target for PB and could make
glucocorticoid therapy less effective. Undoubt-
edly, much more work needs to be done before
definitive conclusions about the role of MIF in
airway cast formation can be made. Neverthe-
less, this illustrates how advancing understand-
ing about disease pathogenesis can be of value
for developing and optimizing therapeutic strate-
gies. Collectively, this review illustrates the
importance of continued work in the field of
pediatric pharmacotherapy so that safe and effec-
tive therapies can be identified for all children.
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